贝林妥欧单抗桥接异基因造血干细胞移植治疗微小残留病阳性急性B淋巴细胞白血病疗效分析

打开文本图片集

【文献标志码】A

Efficacy of blinatumomab as a bridge therapy for allogeneic hematopoietic stem cell transplantation in treatment of minimal residual disease-positive B-lineage acute lymphoblastic leukemia

Liu Jia'，Zhu Lidan’，Gao Shichun'，Liu Huanfeng'，Wang LuI ，Zhang Cheng'，Gao Li′ ，Zhang Xi2 KongPeiyan'，GaoLei² （1.Medical Center of Hematology，The Second Afiliated Hospital of Army Medical University; 2.JinfengLaboratory，TheSecondAffiliated HospitalofArmyMedical University）

【AbstractObective：Toinvestigatefectivestrategiestoduceteighriskofrecurenceafteralogeneichematopoieticstemcell transplantation（alo-HSCT）inpatientswithminimalresidualdisease（MRD）-positiveB-lineageacutelymphoblasticleukemia（BALL）.Methods：AretrospectiveanalysiswasperformedfortenB-ALLpatientswithpositiveMRDbefore ransplantationatourcenter from November2O2 toNovember2024.There werefourmale patientsandsixfemale patients，withamedianageof3O（7-56）years. Ofallpatints，fourrecivedtansplantationfrouelatedoorsndsixeceivedaplodenticaltransplantationfroelativAl tenpatients received blinatumomab（ 28μg/day for14 days for patients ⩾45kg ;5μg/m²/day for14days for patients<45kg）and were bridgedtotheconditioingregimenfoalloHCTwitin7days.Results：Aftertreatmentwithbliatumoab，alltenpatientsached

作者介绍：刘嘉，Email：liujia0917@tmmu.edu.cn，研究方向：造血干细胞移植、恶性血液病的诊治。（剩余9394字）